{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:24:15Z","timestamp":1741238655404,"version":"3.38.0"},"reference-count":56,"publisher":"JLE","issue":"4","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.nephro.2017.03.003","type":"journal-article","created":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T14:55:11Z","timestamp":1520952911000},"page":"189-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Utilisation de l\u2019alfacalcidol et des analogues actifs de la vitamine D dans la maladie r\u00e9nale chronique"],"prefix":"10.1684","volume":"14","author":[{"given":"Pablo Antonio","family":"Ure\u00f1a-Torres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Bover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2017.03.003_bib0285","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.nephro.2014.10.004","article-title":"[Native vitamin D in dialysis patients]","volume":"11","author":"Delanaye","year":"2015","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.nephro.2017.03.003_bib0290","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","article-title":"Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure","volume":"310","author":"Hamdy","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.nephro.2017.03.003_bib0295","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1210\/jcem-67-5-929","article-title":"Low dose calcitriol versus placebo in patients with predialysis chronic renal failure","volume":"67","author":"Nordal","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nephro.2017.03.003_bib0300","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ki.1989.36","article-title":"1,25(OH)2D3\u00a0administration in moderate renal failure: a prospective double-blind trial","volume":"35","author":"Baker","year":"1989","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.03.003_bib0305","first-page":"216","article-title":"Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients with secondary hyperparathyroidism","volume":"40","author":"Fisher","year":"1993","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2017.03.003_bib0310","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1046\/j.1523-1755.2000.00819.x","article-title":"Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group","volume":"57","author":"Indridason","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.03.003_bib0315","first-page":"122","article-title":"Intravenous versus oral calcitriol therapy in renal osteodystrophy: results of a prospective, pulsed and dose-comparable study","volume":"20","author":"Mazzaferro","year":"1994","journal-title":"Miner Electrolyte Metab"},{"key":"10.1016\/j.nephro.2017.03.003_bib0320","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/ki.1994.223","article-title":"Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD","volume":"45","author":"Quarles","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.03.003_bib0325","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/ndt\/gfg595","article-title":"Effect of 18\u00a0months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure","volume":"19","author":"Rix","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.03.003_bib0330","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1097\/01.ASN.0000016082.70875.36","article-title":"Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study","volume":"13","author":"De Sevaux","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.03.003_bib0335","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.transproceed.2007.12.001","article-title":"Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol","volume":"40","author":"Trabulus","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nephro.2017.03.003_bib0340","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1159\/000169179","article-title":"Comparison of the efficacy of two injectable forms of vitamin D3\u00a0and oral one-alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis","volume":"17","author":"el-Reshaid","year":"1997","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nephro.2017.03.003_bib0345","first-page":"e36","article-title":"Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial","volume":"15","author":"Moe","year":"2008","journal-title":"Can J Clin Pharmacol"},{"key":"10.1016\/j.nephro.2017.03.003_bib0350","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1440-1797.2010.01398.x","article-title":"Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients","volume":"16","author":"Kiattisunthorn","year":"2011","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.nephro.2017.03.003_bib0355","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/ki.2011.226","article-title":"No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial","volume":"80","author":"Hansen","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.03.003_bib0360","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/ajkd.1998.v32.pm9708607","article-title":"Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism","volume":"32","author":"Akiba","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.03.003_bib0365","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/tcrm.2006.2.3.297","article-title":"Oral paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease","volume":"2","author":"Cheng","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.nephro.2017.03.003_bib0370","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5414\/CNP65335","article-title":"Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients","volume":"65","author":"Joist","year":"2006","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2017.03.003_bib0375","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1517\/14656566.7.5.617","article-title":"Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease","volume":"7","author":"Cheng","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nephro.2017.03.003_bib0380","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000092033","article-title":"A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3\u00a0and 4","volume":"26","author":"Abboud","year":"2006","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nephro.2017.03.003_bib0385","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3\u00a0and 4\u00a0CKD","volume":"47","author":"Coyne","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.03.003_bib0390","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.10661013","article-title":"A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4\u00a0CKD","volume":"9","author":"Coyne","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.03.003_bib0395","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.03.003_bib0400","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/nep.12029","article-title":"Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism","volume":"18","author":"Ong","year":"2013","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.nephro.2017.03.003_bib0405","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1681\/ASN.2006050445","article-title":"Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2\u00a0diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"18","author":"Eijkelkamp","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.03.003_bib0410","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1111\/j.1523-1755.2005.00755.x","article-title":"Antiproteinuric effect of oral paricalcitol in chronic kidney disease","volume":"68","author":"Agarwal","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.03.003_bib0415","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.ajkd.2011.09.014","article-title":"Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial","volume":"59","author":"Liu","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.03.003_bib0420","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2\u00a0diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2017.03.003_bib0425","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1471-2369-14-163","article-title":"Effect of paricalcitol on renin and albuminuria in non-diabetic stage III\u2013IV chronic kidney disease: a randomized placebo-controlled trial","volume":"14","author":"Larsen","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nephro.2017.03.003_bib0430","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-147-12-200712180-00004","article-title":"Meta-analysis: vitamin D compounds in chronic kidney disease","volume":"147","author":"Palmer","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2017.03.003_bib0435","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cvr\/cvr133","article-title":"Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats","volume":"91","author":"Bae","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.nephro.2017.03.003_bib0440","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/BF03346658","article-title":"Vitamin D deficiency and myocardial structure and function in older men and women: the Hoorn study","volume":"33","author":"Pilz","year":"2010","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.nephro.2017.03.003_bib0445","doi-asserted-by":"crossref","first-page":"16810","DOI":"10.1073\/pnas.0611202104","article-title":"Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals","volume":"104","author":"Bodyak","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nephro.2017.03.003_bib0450","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.nephro.2017.03.003_bib0455","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2013010103","article-title":"Effect of paricalcitol on left ventricular mass and function in CKD \u2013\u00a0the OPERA trial","volume":"25","author":"Wang","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.03.003_bib0460","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ahj.2012.09.018","article-title":"Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease","volume":"164","author":"Tamez","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.nephro.2017.03.003_bib0465","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0002-9149(02)02864-3","article-title":"Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden","volume":"90","author":"Tsang","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nephro.2017.03.003_bib0470","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5002769","article-title":"K\/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients","volume":"73","author":"Barreto","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.03.003_bib0475","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.01040308","article-title":"Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results","volume":"3","author":"Fishbane","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.03.003_bib0480","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","article-title":"Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.03.003_bib0485","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/ndt\/gfr531","article-title":"Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.03.003_bib0490","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ndt\/gfu011","article-title":"Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study","volume":"29","author":"Cozzolino","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.03.003_bib0495","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2215\/CJN.07050714","article-title":"A Randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM)","volume":"10","author":"Wetmore","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.03.003_bib0500","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.03.003_bib0505","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/ndt\/gfs356","article-title":"Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study","volume":"28","author":"Urena-Torres","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.03.003_bib0510","first-page":"1844","article-title":"Cinacalcet for cardiovascular disease in patients undergoing dialysis","volume":"368","author":"Chertow","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.03.003_bib0515","doi-asserted-by":"crossref","first-page":"e001363","DOI":"10.1161\/JAHA.114.001363","article-title":"Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial","volume":"3","author":"Wheeler","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.nephro.2017.03.003_bib0520","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial","volume":"26","author":"Moe","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.03.003_bib0525","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1053\/j.ajkd.2004.01.012","article-title":"Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3\u00a0and 4","volume":"43","author":"Coburn","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.03.003_bib0530","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ndt\/13.suppl_3.68","article-title":"Intermittent oral 1a-hydroxyvitamin D2\u00a0is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients","volume":"13","author":"Frazao","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.03.003_bib0535","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1053\/ajkd.2001.22077","article-title":"Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison","volume":"37","author":"Maung","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.03.003_bib0540","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/ajkd.2000.16193","article-title":"Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism","volume":"36","author":"Frazao","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.03.003_bib0545","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1159\/000089707","article-title":"Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol","volume":"25","author":"Zisman","year":"2005","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nephro.2017.03.003_bib0550","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5414\/CNP70319","article-title":"Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol \u2013\u00a0a dose equivalency and titration study","volume":"70","author":"Fadem","year":"2008","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2017.03.003_bib0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/8756-3282(92)90354-Y","article-title":"Non-aluminic adynamic bone disease in non-dialyzed uremic patients: a new type of osteopathy due to overtreatment?","volume":"13","author":"Cohen-Solal","year":"1992","journal-title":"Bone"},{"key":"10.1016\/j.nephro.2017.03.003_bib0280","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2215\/CJN.11721111","article-title":"Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol","volume":"7","author":"Isakova","year":"2012","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517305497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517305497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2017.03.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:12:16Z","timestamp":1741191136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725517305497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1769725517305497"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2017.03.003","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilisation de l\u2019alfacalcidol et des analogues actifs de la vitamine D dans la maladie r\u00e9nale chronique","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2017.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}